Unknown PHASE4 INTERVENTIONAL 2-arm NCT02982512

Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's Disease

Effects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's Disease

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra

Conditions Deep Brain Stimulation Dexmedetomidine Parkinson Disease

Interventions Dexmedetomidine

Updated 6 times since 2017 Last updated: May 4, 2018 Started: May 1, 2017 Primary completion: Sep 30, 2018 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02982512, this PHASE4 trial focuses on Deep Brain Stimulation and Dexmedetomidine and remains ongoing. Sponsored by Clinica Universidad de Navarra, Universidad de Navarra, it has been updated 6 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2020 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jun 2018 — Jun 2020 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinica Universidad de Navarra, Universidad de Navarra

Data source: Clinica Universidad de Navarra, Universidad de Navarra

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pamplona, Spain